Clinical Trial Detail

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

Complete title: Acalabrutinib in Combination with Anti-CD19 Chimeric Antigen Receptor T-cells (CART) in B-cell Lymphoma

Research Study Number	RG1006269
Principal Investigator	Ajay Gopal, MD
Phase	I/II

Look up trial at NIH

Research Study Description

This phase I/II trial studies the safety of acalabrutinib and axicabtagene ciloleucel in treating patients with B-cell lymphoma. Acalabrutinib may stop the growth of tumor cells by blocking key pathways needed for cell growth. Immunotherapy with axicabtagene ciloleucel is engineered to target a specific surface antigen on lymphoma cells. Acalabrutinib may enhance the efficacy of axicabtagene ciloleucel in treating patients with B-cell lymphoma.

Eligibility Criteria (must meet the following to participate in this study)

** For Eligibility information, please click on the "Look up trial at NIH" link above **

Other eligibility criteria may apply.

Research Study Number

RG1006269

Keywords: Lymphoma, Non-Hodgkin (NHL); Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

RSS feed

Last Modified, June 25, 2019